Core Insights - Fifty1 AI Labs, LLC has successfully completed the REVIVE Adaptive Platform Trial, the largest Long COVID study to date, addressing a health crisis affecting approximately 400 million people globally and 15% of COVID-19 survivors, with an economic burden exceeding USD 1 trillion annually [1][2] - The trial demonstrates a clear treatment benefit for Long COVID, aligning with Fifty 1 Labs, Inc.'s vision to revolutionize healthcare through AI-driven drug repurposing and functional medicine, targeting the $5.68 trillion biotech market [2][3] - The company aims to achieve a $50 million valuation and lead the $320.6 billion functional medicine market, enhancing investor confidence and positioning for uplisting to OTCQB by Q1 2026 and NASDAQ in the coming years [2][7] Company Achievements - The REVIVE Trial enrolled over 600 participants, achieving the fastest recruitment for a study of its kind, showcasing operational excellence and strategic partnerships with leading institutions [3][4] - Fifty1 AI Labs' proprietary AI platform, supported by a $1 million R&D investment, optimizes drug candidate selection and accelerates clinical research efficiency, setting a new standard in the industry [4][5] - The findings from the REVIVE Trial are expected to establish a foundation for polypharmacy-based treatment regimens, unlocking significant opportunities for intellectual property development and potential annual revenue in the billions [5][6] Strategic Initiatives - The company is pursuing regulatory pathways to bring novel therapies to market and establishing R&D hubs in Vancouver, alongside strategic partnerships with pharmaceutical leaders [7] - Upcoming initiatives include the launch of a minimum viable product website by July 24, 2025, and a fully interactive website by July 31, 2025, aimed at enhancing investor engagement [7] - A virtual shareholder teleconference is scheduled for July 28, 2025, to provide insights into the company's transformative vision and progress toward uplisting [7]

In Brief Formula 1 could have a new U.S. streaming service home soon. Apple is in talks to purchase the rights as it looks to further invest in live sports, the Financial Times reports.Apple already has deals for Major League Baseball and Major League Soccer. ESPN’s F1 contract ends next year. But Apple will be up against ESPN, as well as likely other bidders. This latest news comes as Apple enjoys its first blockbuster in-theaters hit with its new F1 movie, produced by F1 star Lewis Hamilton. F1-related e ...

齐鲁晚报·齐鲁壹点 尹睿 引擎轰鸣，风驰电掣，时速300km的"速度与激情"让苹果公司出品的院线电影《F1：狂飙飞车》的全球票房达到2.93亿美元，刷新苹果院 线业务历史最高票房纪录。 随着电影的热映，世界一级方程式锦标赛（F1）也再次成为公众瞩目的焦点，其作为赛车界的顶级赛事，每年的运营成本高达数十亿美 元，堪称"金钱与速度的极致博弈"。在如此惊人的成本压力下，这场"烧钱游戏"究竟依托哪些收入来源维持运转？又是谁在为其巨额开 销"买单"？ F1的"吸金利器"：媒体版权 作为一个商业模式高度成熟的全球体育赛事，F1的收入来源大致可以分为四类：媒体版权、赛事推广、赞助费以及其他衍生收入。据国 际汽联公布的2024赛季财报显示，F1全年总收入达36.5亿美元，媒体版权收入占总收入的33%左右，约12.96亿美元，为F1最大收入来 源。 F1赛事的全球转播网络覆盖数百个国家和地区，赛事本身的全球影响力与受众黏性使其转播权成为各大媒体平台竞相争夺的资源，转播 商们在将比赛画面展现在亿万观众眼前的同时，也通过广告投放、付费订阅等方式实现商业变现。目前，F1美国地区每年转播费约9000 万美元，英国则超过2.5亿美元。 ...

Company Overview - MedRhythms, Inc. is pioneering next-generation neurotherapeutics aimed at improving walking, mobility, and related functional outcomes through a proprietary technology platform that integrates sensors, software, and music with advanced neuroscience [5] - The company has developed a pipeline of products targeting various neurological conditions, including stroke, multiple sclerosis, and Parkinson's disease [5] Leadership Transition - Larry Jasinski has been appointed as the new Chief Executive Officer, effective immediately, succeeding co-founder Brian Harris, who will transition to Chief Scientific Officer [1][3] - Jasinski brings over 30 years of executive leadership experience in the medical device and neurotechnology industries, including a successful IPO at Lifeward and national reimbursement for the first exoskeleton system for spinal cord injury [2] Strategic Growth Plans - The appointment of Jasinski is seen as a critical inflection point for MedRhythms, as the company prepares for national expansion of its home-use products, InTandem® for chronic stroke and Movive™ for Parkinson's disease, both of which are FDA-listed Class II devices [4] - The company aims to accelerate market adoption and build on its clinical foundation to reach more patients with chronic health and mobility conditions [4] Market Position and Vision - MedRhythms has established clinical data supporting the effectiveness of its products and operates in sizable market segments, having gained coverage from CMS and other entities [4] - The company is focused on transforming patients' lives and is positioned to become a valuable business entity in the neurorehabilitation space [4]

今天分享的是：2025年中国美容行业的白皮书 防脱经济因年轻群体的"脱发焦虑"持续升温。2021年中国脱发人群超2.5亿，平均年龄30.1岁，比上一代提前20年。618购物节期 间，防脱产品需求增长33.1%，其中防脱洗发水是入门首选，2020年销售额达15.4亿元；米诺地尔等外用药增长迅猛，某品牌年 销售额从2018年的1100万元飙升至2021年的1.16亿元；植发作为"终极解决方案"，2020年市场规模达134亿元，但渗透率仅 0.2%，未来增长空间巨大。 纯净美容（Clean Beauty） 虽属小众但潜力显著。87%的消费者关注香水是否含天然成分，64%在意过敏原，海外品牌如澳大利 亚ONE SEED已将有机成分占比提升至80%。本土品牌则结合中医智慧，佰草集、东边野兽等以"草本配方"主打敏感肌市场，契 合了消费者对"天然安全"的追求。政策红利也在释放，2021年起进口普通化妆品免除动物测试，为更多国际纯净品牌进入中国 扫清障碍。 报告共计：43页 后疫情时代中国美容市场：消费趋势迭代与新赛道崛起 随着2023年初疫情防控政策的调整，中国美容市场迎来了新的发展机遇。经历了特殊时期的消费习惯重塑，从护 ...

IRVINE, Calif., June 30, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental premarket approval (sPMA) application for SKINVIVE by JUVÉDERM® to reduce neck lines for the improvement of neck appearance. SKINVIVE by JUVÉDERM® is currently approved in the U.S. to improve skin smoothness of the cheeks in adults over the age of 21. "SKINVIVE by JUVÉDERM® is an injectable version of hyaluron ...

i：指本次可转债当年票面利率。 （1）本次可转债采用每年付息一次的付息方式，计息起始日为本次可转债发 行首日。 （2）付息日：每年的付息日为自本次可转债发行首日起每满一年的当日。如 该日为法定节假日或休息日，则顺延至下一个交易日，顺延期间不另付息。每相 邻的两个付息日之间为一个计息年度。 证券代码：300740 证券简称：水羊股份 债券代码：123188 债券简称：水羊转债 华泰联合证券有限责任公司 关于水羊集团股份有限公司 向不特定对象发行可转换公司债券 受托管理事务报告 （2024 年度） 债券受托管理人 （深圳市前海深港合作区南山街道桂湾五路 128 号前海深港基金小镇 B7 栋 二〇二五年六月 重要声明 本报告依据《可转换公司债券管理办法》 （以下简称"《管理办法》"）、 《水羊 集团股份有限公司（作为发行人）与华泰联合证券有限责任公司（作为受托管理 人）关于水羊集团股份有限公司向不特定对象发行可转换公司债券之债券受托管 理协议》 （以下简称"《受托管理协议》"）、 《水羊集团股份有限公司向不特定对象 发行可转换公司债券并在创业板上市募集说明书》 （以下简称"《募集说明书》"）、 《水羊集团股份有限公 ...

This presentation and the accompanying oral presentation, if any, contain forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to future results of operations and financial position, planned products and services, business strategy and plans, objectives of management for future operations of Health Catalyst, Inc. and its subsidiaries ("Health Catalyst" or the "Company"), market size and growth opportunities, competitive p ...

中国意大利商会的金熊猫奖创办于2009年，并得到意大利驻华大使馆和意大利驻上海总领事馆的大力支 持，颁奖活动每年举办一次。今年共设立了八大奖项，旨在表彰之前一年在中国投资、增长、发展韧性 和创新方面作出杰出贡献的意大利和中国会员企业。该奖项不仅是对意大利的创造力、创新精神与企业 家精神的褒奖，更是对所有在华市场各领域彰显"意大利制造"实力与品质的企业认可，也是推动中意经 贸关系发展的重要平台。 来源：环球网 6月14日，第十四届中国意大利商会"金熊猫奖"颁奖盛典在上海如期举行。作为中国意大利商会年度最 负盛名的活动之一，来自中意两国的数百家企业、企业家、商会会员以及意大利和中国的多个机构代 表，共同见证了这一荣耀时刻。而意大利高端家居品牌NATUZZI也连续两年斩获"2025金熊猫奖之意大 利卓越奖"，这一奖项旨在表彰意大利公司在奢华生活、时尚、奢侈品和高级商品、生活方式、设计、 零售和数字领域最有效地代表了意大利制造的卓越品质。 NATUZZI作为最早进入中国的意大利进口家具品牌之一，一直积极投身于推动中意两国之间的商业与 文化交流。除了赞助2025年度金熊猫奖颁奖典礼及中国意大利商会圆桌会议之外，NATU ...

Group 1 - USANA President and CEO Jim Brown has been elected to the Board of Directors of the Direct Selling Association (DSA) for a three-year term [1] - Jim Brown has over 25 years of leadership experience, with 19 years at USANA in various roles [1] - The DSA has been a national trade association for direct selling companies for over a century, generating $36.7 billion in retail sales in 2023 [2] Group 2 - In 2023, 6.1 million entrepreneurs in the U.S. engaged in direct selling, providing a personalized buying experience for customers [2] - DSA CEO David Grimaldi expressed confidence in Jim Brown's impact on the board, highlighting his significant experience in the industry [3] - USANA has been recognized for its quality nutritional and lifestyle products for over 30 years [4]